You are here: Industry Insights > gene therapy

News List

Cobra Produces Master Cell Banks for CombiGene’s Gene Therapy contractpharma
August 19, 2020
A milestone in the manufacture of a drug candidate for the treatment of focal epilepsy.
Catalent’s Harmans Site Approved to Manufacture AveXis’ Gene Therapy contractpharma
August 10, 2020
To produce commercial drug substance intermediate for AveXis’ spinal muscular atrophy gene therapy at its manufacturing facility in Harmans, MD.
Catalent Partners with Gene Editing Company Editas contractpharma
July 30, 2020
Will provide services for the development and manufacturing of Editas’ cell and gene medicines.
UK invests $127m to scale up Covid-19 vaccine manufacturing pharmaceutical-technology.
July 24, 2020
The Government of UK has announced an investment of £100m ($127m) to scale up manufacturing of Covid-19 vaccine and gene therapy in the country.
Orchard Therapeutics, MolMed Extend Gene Therapy Mfg. Pact contractpharma
July 10, 2020
MolMed to support the development and manufacture of vectors and drug products for Orchard’s investigational hematopoietic stem cell (HSC) gene therapies.
Emergent BioSolutions Enters Viral Vector and Gene Therapy Arena contractpharma
June 19, 2020
Invests $75mn in Canton site, advanced therapy CDMO drug substance manufacturing services expected to be available beginning in 2023.
Sanofi hands back rights to Oxford Biomedica gene therapies pharmatimes
June 09, 2020
Sanofi is handing back rights to two gene therapy programmes it acquired from Oxford Biomedica more than 10 years ago.
Novasep, Lysogene Enter Gene Therapy Collaboration contractpharma
May 28, 2020
Novasep and Lysogene have entered an agreement for the development and manufacturing of LYS-GM101, an AAVrh10-based gene therapy drug candidate for the treatment of GM1 gangliosidosis, a rare neuronopathic lysosomal storage disorder.
Dyno Therapeutics launches with deals from Novartis and Sarepta pharmaceutical-technology
May 13, 2020
Biotechnology company Dyno Therapeutics has launched from stealth mode with focus on using artificial intelligence (AI) technology to develop adeno-Associated Virus (AAV) vectors.
Noga Therapeutics and Lonza to develop Autologous Lentiviral Gene Therapy on the Cocoon Platform expresspharma
May 13, 2020
The Cocoon Platform is a closed, highly customizable and scalable platform with minimal touchpoints, which will help Noga Therapeutics to accelerate the development of lentiviral gene therapies.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page